Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction‐associated steatotic liver disease: A prospective, multicentre, observational study

Significant improvements in body weight, liver enzymes, and glycaemic control were observed in 70 patients after 48 weeks of oral semaglutide treatment.

• Body weight, liver enzymes, lipid profile, and glycaemic control showed significant enhancement after 48 weeks (all p < 0.01).
• Controlled attenuation parameter values decreased significantly from baseline to 48 weeks (p < 0.01).
• Changes in alanine aminotransferase and controlled attenuation parameter values were significantly correlated with changes in body weight (both p < 0.01).
• Markers of liver fibrosis, including type IV collagen 7S and liver stiffness measurement, significantly decreased over the treatment period (all p < 0.01).
• The most common adverse events were Grades 1-2 gastrointestinal symptoms, with nausea occurring in 28.8% of patients.

AI simplified